Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

202313 citationsJournal Articlegreen Open Access

Authors

Susanne A. Gatz · Birmingham Women’s and Children’s NHS Foundation Trust

Anne C. Harttrampf · Inserm

Caroline Brard · Université Paris-Sud

Francisco Bautista · Hospital Infantil Universitario Niño Jesús

Nicolás André · Centre National de la Recherche Scientifique

Samuel Abbou · Institut Gustave Roussy

Jonathan Rubino

Abstract

Adavosertib-carboplatin combination exhibited significant hematologic toxicity. Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA-damaging therapy in molecularly enriched pediatric cancers.

Topics & Keywords

Cancer therapeutics and mechanisms Neuroblastoma Research and Treatments Renal and related cancers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 30, Issue 4, pp. 741-753

DOI: 10.1158/1078-0432.ccr-23-2959

Field-Weighted Citation Impact: 1.99